EMT is thought to be a marker of tumor progression, with tumors that express mesenchymal markers having a greater tendency to be invasive and metastasize than those tumors only expressing epithelial markers. Tumors expressing mesenchymal markers are thought to have a worse prognosis than tumors expressing epithelial markers.
OSI’s Oncology research is focused on understanding the science of EMT in solid tumors in order to develop effective and safe mechanism-based therapeutic agents.
Common Questions:
(Click on each question to learn more)
For more information on Molecular Targeted Therapies in EMT, please contact Medical Information. |

OSI Oncology is proud to sponsor the AACR Special Conferences Series on "EMT and Cancer Prevention and Treatment" to be held from February 28-March 2, 2010 in Arlington, Virginia.
Learn more*Our research organization is focused on the discovery of novel small molecule compounds targeted against the underlying molecular mechanisms of the pathogenesis of cancer. Our strategy is to develop mechanism-based approaches to drug discovery directed at the processes underlying the role of the Epithelial Mesenchymal Transition (EMT) in the development of cancer.
Learn more*This website is not endorsed by OSI, and OSI is not responsible for its content.